





ANNOUNCEMENT TITLE	ASTRO-Myovant Sciences-Pfizer Alliance New Combination Therapy Challenge
PROGRAM YEAR	2022
MECHANISM	Advancing-Medicine-Together Scientific Challenges
PA NUMBER	SC-2022-01-MYOV-PFE
GRANTOR	Myovant Sciences-Pfizer Alliance
OPEN DATE	March 29, 2022
FAQ Latest Update	May 27, 2022

FREQUENTLY ASKED QUESTIONS (FAQ)

#	Question	Answer
1	Is theranostics/molecular radiotherapy included in the scope of this opportunity?	Yes, theranostics/radioligand/radiopharmaceutical therapy is included in the scope of this opportunity on the use of relugolix with radiotherapy.
2	Are there additional funds available (outside of the granted amount) to cover the cost of relugolix among patients for whom it is not covered by their insurance?	Neither ASTRO nor the Myovant Sciences-Pfizer Alliance have the ability to provide product on a per patient basis. However, product (relugolix) can be requested as a part of the overall research proposal submission. Relugolix product supply requests are not included in the grant funding limit. The independent Challenge Judging Panel, as assembled and led by ASTRO, will evaluate these kinds of requests in the context of the whole submission.
3	How do I indicate relugolix in the Pfizer Investigator Sponsored Research (ISR) Grant System's "Pfizer Drug of Interest" field?	<p>Please select "Invited" to the "Pfizer Drug of Interest" field.</p>  <p>Further down in the application, you will be asked how many Pfizer drugs you are requesting, followed by the name of the drug and quantities. Please select "Invited" again and type "relugolix" in the provided field.</p>  <p>(Note: Relugolix, as a Myovant drug, is not on Pfizer ISP's existing drug drop-down list.)</p>
4	What should I do if I have questions about the CyberGrants portal or "get stuck" in the process of completing my online grant application?	<p>Please send an email to: GlobalMedicalGrants@pfizer.com for all tech support or grant application process questions.</p> <p>All scientific, topic-specific questions about this PA should be directed to the Department of Scientific Affairs at science@astro.org.</p>